AMRX: overvalued.
Figures as of the 2026-10-19 close.
Amneal Pharmaceuticals Inc carries debt worth 84.55 times its shareholders' equity, a heavy load. Its current assets cover its short-term liabilities 2.20 times.
Its Altman Z-Score, computed from its latest annual report, falls in the grey zone: not the pattern that has preceded bankruptcies, but not clear of it either. It is a statistical warning light, not a forecast.
It scores 7 out of 9 on the Piotroski F-Score, which checks whether profitability, leverage and efficiency improved from one annual report to the next. Seven or more is strong; three or fewer is weak. Which tests it passes, and the red flags in its accounts, are in the full analysis.